Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043808 · ClinicalTrials.gov registry record
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 25,586
- Enrollment target
NCT02043808 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 25,586 participants.
The verdict
NCT02043808 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 25,586 participants
- Enrollment target
Study Summary
The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,586 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043808
The ClinicalTrials.gov registry entry for NCT02043808 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25,586 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02043808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043808 about?
NCT02043808 is a clinical study titled "The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage". The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
What is the current status of trial NCT02043808?
This trial is currently completed. The enrollment target is 25,586 participants. The study started on 2014-01. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT02043808?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.